{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:13:47Z","timestamp":1759104827067,"version":"3.44.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hereditas"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Gastric cancer (GC) remains a global health challenge due to its high morbidity, late-stage diagnosis, and limited therapeutic options. long non-coding RNA PANDAR has been implicated in tumorigenesis across multiple cancers, yet its role in GC pathogenesis and diagnostic utility is still unclear. The purpose of this study is to elucidate the diagnostic value of serum PANDAR and its regulatory mechanisms in GC progression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>lncRNA PANDAR levels were quantified in serum from 112 GC patients and 98 benign controls using RT-qPCR. The diagnostic value of lncRNA PANDAR was analyzed by ROC curve. Functional experiments (CCK-8, Transwell assays) and dual-luciferase reporter assays were conducted in HGC-27 and BGC-823 cells to explore the function of PANDAR in cell proliferation, migration, and invasion. The interaction between PANDAR and miR-637 was validated via bioinformatics prediction and co-inhibition assay.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Serum PANDAR was significantly upregulated in GC patients (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001) and exhibited high diagnostic accuracy (AUC\u2009=\u20090.913). Elevated PANDAR associated with advanced TNM stage (<jats:italic>P<\/jats:italic>\u2009=\u20090.047), lymph node metastasis (<jats:italic>P<\/jats:italic>\u2009=\u20090.023), and digestive system history (<jats:italic>P<\/jats:italic>\u2009=\u20090.035). PANDAR knockdown suppressed GC cell proliferation, migration, and invasion, effects reversed by co-inhibition of miR-637.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>lncRNA PANDAR is a promising non-invasive diagnostic indicator of GC, and may serve as a biomarker for GC diagnosis and therapy. lncRNA PANDAR regulates the progression of GC through sponge miR-637.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s41065-025-00511-7","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T14:00:47Z","timestamp":1753538447000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The diagnostic and predictive value of LncRNA PANDAR in gastric cancer and its regulation of gastric cancer progression via miR-637"],"prefix":"10.1186","volume":"162","author":[{"given":"Weikang","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiling","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huazhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingjia","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinqiang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,26]]},"reference":[{"issue":"24","key":"511_CR1","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1097\/CM9.0000000000003442","volume":"137","author":"Y Wu","year":"2024","unstructured":"Wu Y, He S, Cao M, Teng Y, Li Q, Tan N, et al. Comparative analysis of cancer statistics in China and the united States in 2024. Chin Med J (Engl). 2024;137(24):3093\u2013100.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"511_CR2","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1097\/SLA.0000000000003833","volume":"275","author":"Y Cao","year":"2022","unstructured":"Cao Y, He H, Li R, Liu X, Chen Y, Qi Y, et al. Latency-associated peptide identifies immunoevasive subtype gastric Cancer with poor prognosis and inferior chemotherapeutic responsiveness. Ann Surg. 2022;275(1):e163\u201373.","journal-title":"Ann Surg"},{"issue":"7","key":"511_CR3","doi-asserted-by":"publisher","first-page":"101042831771462","DOI":"10.1177\/1010428317714626","volume":"39","author":"Z Song","year":"2017","unstructured":"Song Z, Wu Y, Yang J, Yang D, Fang X. Progress in the treatment of advanced gastric cancer. Tumour Biol. 2017;39(7):1010428317714626.","journal-title":"Tumour Biol"},{"issue":"5","key":"511_CR4","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.gassur.2024.02.023","volume":"28","author":"C Pang","year":"2024","unstructured":"Pang C, Ma Y, Shi W, Zi M, Chen J, Liang C, et al. Prognostic significance of serum tumor markers in various pathologic subtypes of gastric cancer. J Gastrointest Surg. 2024;28(5):694\u2013702.","journal-title":"J Gastrointest Surg"},{"key":"511_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cancergen.2024.06.002","volume":"286\u2013287","author":"D Sonkin","year":"2024","unstructured":"Sonkin D, Thomas A, Teicher BA. Cancer treatments: past, present, and future. Cancer Genet. 2024;286\u2013287:18\u201324.","journal-title":"Cancer Genet"},{"issue":"2","key":"511_CR6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.21147\/j.issn.1000-9604.2025.02.12","volume":"37","author":"H Liu","year":"2025","unstructured":"Liu H, Dilger JP. Different strategies for cancer treatment: targeting cancer cells or their neighbors? Chin J Cancer Res. 2025;37(2):289\u201392.","journal-title":"Chin J Cancer Res"},{"key":"511_CR7","unstructured":"Joshi RM, Telang B, Soni G, Khalife AJO, Medicine T. Overview of perspectives on cancer,newer therapies,and future directions. 2024;10(3):105\u20139."},{"key":"511_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.cancergen.2023.10.001","volume":"278\u2013279","author":"H Liu","year":"2023","unstructured":"Liu H, Tang T. Pan-cancer genetic analysis of disulfidptosis-related gene set. Cancer Genet. 2023;278\u2013279:91\u2013103.","journal-title":"Cancer Genet"},{"key":"511_CR9","doi-asserted-by":"publisher","first-page":"108302","DOI":"10.1016\/j.pharmthera.2022.108302","volume":"240","author":"H Liu","year":"2022","unstructured":"Liu H, Dilger JP, Lin J. A pan-cancer-bioinformatic-based literature review of TRPM7 in cancers. Pharmacol Ther. 2022;240:108302.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"511_CR10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40364-024-00620-x","volume":"12","author":"H Liu","year":"2024","unstructured":"Liu H, Weng J, Huang CL, Jackson AP. Voltage-gated sodium channels in cancers. Biomark Res. 2024;12(1):70.","journal-title":"Biomark Res"},{"issue":"2","key":"511_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/cac2.12108","volume":"41","author":"YT Tan","year":"2021","unstructured":"Tan YT, Lin JF, Li T, Li JJ, Xu RH, Ju HQ. LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer. Cancer Commun (Lond). 2021;41(2):109\u201320.","journal-title":"Cancer Commun (Lond)"},{"issue":"12","key":"511_CR12","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1016\/j.molcel.2022.05.027","volume":"82","author":"AB Herman","year":"2022","unstructured":"Herman AB, Tsitsipatis D, Gorospe M. Integrated LncRNA function upon genomic and epigenomic regulation. Mol Cell. 2022;82(12):2252\u201366.","journal-title":"Mol Cell"},{"issue":"4","key":"511_CR13","doi-asserted-by":"publisher","first-page":"4206","DOI":"10.1002\/jcp.27179","volume":"234","author":"H Mehrad-Majd","year":"2019","unstructured":"Mehrad-Majd H, Akhtari J, Haerian MS, Ravanshad Y. Clinicopathological and prognostic value of LncRNA PANDAR expression in solid tumors: evidence from a systematic review and meta-analysis. J Cell Physiol. 2019;234(4):4206\u201316.","journal-title":"J Cell Physiol"},{"key":"511_CR14","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.3389\/fonc.2019.01337","volume":"9","author":"L Han","year":"2019","unstructured":"Han L, Wang B, Wang R, Wang Z, Gong S, Chen G, et al. Prognostic and clinicopathological significance of long Non-coding RNA PANDAR expression in Cancer patients: A Meta-Analysis. Front Oncol. 2019;9:1337.","journal-title":"Front Oncol"},{"key":"511_CR15","doi-asserted-by":"crossref","unstructured":"Zou Y, Zhong Y, Wu J, Xiao H, Zhang X, Liao X et al. Long non-coding PANDAR as a novel biomarker in human cancer: A systematic review. Cell Prolif. 2018;51(1).","DOI":"10.1111\/cpr.12422"},{"key":"511_CR16","doi-asserted-by":"publisher","first-page":"4877","DOI":"10.2147\/OTT.S169823","volume":"11","author":"S Gao","year":"2018","unstructured":"Gao S, Zhao ZY, Wu R, Zhang Y, Zhang ZY. Prognostic value of long noncoding RNAs in gastric cancer: a meta-analysis. Onco Targets Ther. 2018;11:4877\u201391.","journal-title":"Onco Targets Ther"},{"key":"511_CR17","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.2147\/CMAR.S201935","volume":"11","author":"Z Yang","year":"2019","unstructured":"Yang Z, Sun Y, Liu R, Shi Y, Ding S. Plasma long noncoding RNAs PANDAR, FOXD2-AS1, and SMARCC2 as potential novel diagnostic biomarkers for gastric cancer. Cancer Manag Res. 2019;11:6175\u201384.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"511_CR18","doi-asserted-by":"publisher","first-page":"19498","DOI":"10.1038\/s41598-022-23938-8","volume":"12","author":"B El-Helkan","year":"2022","unstructured":"El-Helkan B, Emam M, Mohanad M, Fathy S, Zekri AR, Ahmed OS. Long non-coding RNAs as novel prognostic biomarkers for breast cancer in Egyptian women. Sci Rep. 2022;12(1):19498.","journal-title":"Sci Rep"},{"issue":"2","key":"511_CR19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","volume":"136","author":"DP Bartel","year":"2009","unstructured":"Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215\u201333.","journal-title":"Cell"},{"issue":"1","key":"511_CR20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41419-021-04364-6","volume":"13","author":"H Sang","year":"2022","unstructured":"Sang H, Zhang W, Peng L, Wei S, Zhu X, Huang K, et al. Exosomal circRELL1 serves as a miR-637 sponge to modulate gastric cancer progression via regulating autophagy activation. Cell Death Dis. 2022;13(1):56.","journal-title":"Cell Death Dis"},{"key":"511_CR21","doi-asserted-by":"publisher","first-page":"637761","DOI":"10.3389\/fonc.2021.637761","volume":"11","author":"D Yang","year":"2021","unstructured":"Yang D, Hu Z, Zhang Y, Zhang X, Xu J, Fu H, et al. CircHIPK3 promotes the tumorigenesis and development of gastric Cancer through miR-637\/AKT1 pathway. Front Oncol. 2021;11:637761.","journal-title":"Front Oncol"},{"issue":"19","key":"511_CR22","doi-asserted-by":"publisher","first-page":"5879","DOI":"10.7150\/jca.55181","volume":"12","author":"Y Qing","year":"2021","unstructured":"Qing Y, Li Q, Zhao LY, Shi P, Shan JL, Zhang W. LncRNA-PANDAR regulates the progression of thyroid carcinoma by targeting miR-637\/KLK4. J Cancer. 2021;12(19):5879\u201387.","journal-title":"J Cancer"},{"issue":"4","key":"511_CR23","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1159\/000506509","volume":"38","author":"P Petryszyn","year":"2020","unstructured":"Petryszyn P, Chapelle N, Matysiak-Budnik T. Gastric cancer: where are we heading?? Dig Dis. 2020;38(4):280\u20135.","journal-title":"Dig Dis"},{"key":"511_CR24","doi-asserted-by":"crossref","unstructured":"Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci. 2020;21(11).","DOI":"10.3390\/ijms21114012"},{"issue":"17","key":"511_CR25","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.3748\/wjg.v29.i17.2515","volume":"29","author":"T Matsuoka","year":"2023","unstructured":"Matsuoka T, Yashiro M. Novel biomarkers for early detection of gastric cancer. World J Gastroenterol. 2023;29(17):2515\u201333.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"511_CR26","doi-asserted-by":"publisher","first-page":"6903","DOI":"10.1038\/s41467-022-34703-w","volume":"13","author":"D Chen","year":"2022","unstructured":"Chen D, Fu M, Chi L, Lin L, Cheng J, Xue W, et al. Prognostic and predictive value of a pathomics signature in gastric cancer. Nat Commun. 2022;13(1):6903.","journal-title":"Nat Commun"},{"issue":"17","key":"511_CR27","doi-asserted-by":"publisher","first-page":"e37046","DOI":"10.1016\/j.heliyon.2024.e37046","volume":"10","author":"L Ou","year":"2024","unstructured":"Ou L, Liu H, Peng C, Zou Y, Jia J, Li H, et al. Helicobacter pylori infection facilitates cell migration and potentially impact clinical outcomes in gastric cancer. Heliyon. 2024;10(17):e37046.","journal-title":"Heliyon"},{"issue":"11","key":"511_CR28","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1158\/1078-0432.CCR-19-3231","volume":"26","author":"A Sathe","year":"2020","unstructured":"Sathe A, Grimes SM, Lau BT, Chen J, Suarez C, Huang RJ, et al. Single-Cell genomic characterization reveals the cellular reprogramming of the gastric tumor microenvironment. Clin Cancer Res. 2020;26(11):2640\u201353.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"511_CR29","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3233\/CBM-182251","volume":"25","author":"Y Li","year":"2019","unstructured":"Li Y, Su X, Pan H. Inhibition of LncRNA PANDAR reduces cell proliferation, cell invasion and suppresses EMT pathway in breast cancer. Cancer Biomark. 2019;25(2):185\u201392.","journal-title":"Cancer Biomark"},{"issue":"2","key":"511_CR30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.pulmoe.2021.05.005","volume":"29","author":"T Jia","year":"2023","unstructured":"Jia T, Zhang Q, Xu H, Liu H, Gu X. The function of miR-637 in non-small cell lung cancer progression and prognosis. Pulmonology. 2023;29(2):111\u20138.","journal-title":"Pulmonology"},{"key":"511_CR31","doi-asserted-by":"crossref","unstructured":"Castanhole-Nunes MMU, Tunissiolli NM, Oliveira A, Mattos MF, Galbiatti-Dias ALS, Kawasaki-Oyama RS et al. MiR-612, miR-637, and miR-874 can regulate VEGFA expression in hepatocellular carcinoma cell lines. Genes (Basel). 2022;13(2).","DOI":"10.3390\/genes13020282"},{"key":"511_CR32","doi-asserted-by":"crossref","unstructured":"Li R, Huang Y, Liu H, Dilger JP, Lin JJCR. Abstract 2162: comparing volatile and intravenous anesthetics in a mouse model of breast cancer metastasis. 2018;78(13 Supplement):2162\u20132162.","DOI":"10.1158\/1538-7445.AM2018-2162"},{"key":"511_CR33","doi-asserted-by":"crossref","unstructured":"Kang ZR, Jiang S, Han JX, Gao Y, Xie Y, Chen J et al. Deficiency of BCAT2-mediated branched-chain amino acid catabolism promotes colorectal cancer development. 2024;1870(2):12.","DOI":"10.1016\/j.bbadis.2023.166941"},{"issue":"6","key":"511_CR34","doi-asserted-by":"publisher","first-page":"167250","DOI":"10.1016\/j.bbadis.2024.167250","volume":"1870","author":"SJ Lee","year":"2024","unstructured":"Lee SJ, Jeon SH, Cho S, Kim CM, Yoo JK, Oh SH, et al. hsa-miR-CHA2, a novel microrna, exhibits anticancer effects by suppressing Cyclin E1 in human non-small cell lung cancer cells. Biochim Biophys Acta Mol Basis Dis. 2024;1870(6):167250.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"11","key":"511_CR35","doi-asserted-by":"publisher","first-page":"50","DOI":"10.14715\/cmb\/2018.64.11.10","volume":"64","author":"J Zhang","year":"2018","unstructured":"Zhang J, Liu WL, Zhang L, Ge R, He F, Gao TY, et al. MiR-637 suppresses melanoma progression through directly targeting P-REX2a and inhibiting PTEN\/AKT signaling pathway. Cell Mol Biol (Noisy-le-grand). 2018;64(11):50\u20137.","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"issue":"2","key":"511_CR36","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1139\/bcb-2019-0079","volume":"98","author":"E Guan","year":"2020","unstructured":"Guan E, Xu X, Xue F. circ-NOTCH1 acts as a sponge of miR-637 and affects the expression of its target gene Apelin to regulate gastric cancer cell growth. Biochem Cell Biol. 2020;98(2):164\u201370.","journal-title":"Biochem Cell Biol"},{"issue":"6","key":"511_CR37","first-page":"1019","volume":"42","author":"L Hengrui","year":"2022","unstructured":"Hengrui L. Toxic medicine used in traditional Chinese medicine for cancer treatment: are ion channels involved? J Tradit Chin Med. 2022;42(6):1019\u201322.","journal-title":"J Tradit Chin Med"},{"issue":"2","key":"511_CR38","first-page":"209","volume":"43","author":"L Hengrui","year":"2023","unstructured":"Hengrui L. An example of toxic medicine used in traditional Chinese medicine for cancer treatment. J Tradit Chin Med. 2023;43(2):209\u201310.","journal-title":"J Tradit Chin Med"},{"key":"511_CR39","doi-asserted-by":"publisher","first-page":"7178414","DOI":"10.1155\/2021\/7178414","volume":"2021","author":"S Zhou","year":"2021","unstructured":"Zhou S, Fan X, Du X, Liu S, Sun H, Zhang Y. Effect of traditional Chinese medicine combined with bladder perfusion with hydroxycamptothecin on color ultrasound and clinical efficacy in patients with bladder Cancer surgery. Evid Based Complement Alternat Med. 2021;2021:7178414.","journal-title":"Evid Based Complement Alternat Med"},{"issue":"20","key":"511_CR40","doi-asserted-by":"publisher","first-page":"106443","DOI":"10.3748\/wjg.v31.i20.106443","volume":"31","author":"HR Liu","year":"2025","unstructured":"Liu HR. Harnessing traditional medicine and biomarker-driven approaches to counteract trichostatin A-induced esophageal cancer progression. World J Gastroenterol. 2025;31(20):106443.","journal-title":"World J Gastroenterol"}],"container-title":["Hereditas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-025-00511-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41065-025-00511-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-025-00511-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T01:43:21Z","timestamp":1757295801000},"score":1,"resource":{"primary":{"URL":"https:\/\/hereditasjournal.biomedcentral.com\/articles\/10.1186\/s41065-025-00511-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,26]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["511"],"URL":"https:\/\/doi.org\/10.1186\/s41065-025-00511-7","relation":{},"ISSN":["1601-5223"],"issn-type":[{"type":"electronic","value":"1601-5223"}],"subject":[],"published":{"date-parts":[[2025,7,26]]},"assertion":[{"value":"4 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided written informed consent prior to participation, and the study protocol was reviewed and approved by an independent ethics committee affiliated with the hospital of Putuo Hospital, Shanghai University of Traditional Chinese Medicine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"144"}}